Date: 2016-04-26
Type of information: Nomination
Compound:
Company: PTC Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 26, 2016, PTC Therapeutics announced that Tuyen Ong, M.D. has been promoted to Chief Medical Officer. Dr. Ong joined PTC in 2014 as the Senior Vice President, Head of Clinical Development and Translational Research. He succeeds Robert J. Spiegel M.D., FACP, who has served as PTC's Chief Medical Officer since 2011. Dr. Spiegel will remain active in a consulting role, continuing to support PTC's development programs and its global clinical and regulatory activities. Prior to joining PTC in 2014, Dr. Ong served as Vice President of Global Clinical Development and Operations at Valeant Pharmaceuticals (previously Bausch and Lomb). Dr. Ong played a key role in Bausch and Lomb's filing of new drug applications and its transformation into a global competitor in the specialty care sector. Previously, Dr. Ong worked at Pfizer Inc., developing drugs for diseases with high unmet medical need in various disease areas including respiratory, gastrointestinal, hepatology, and ophthalmology. Dr. Ong holds a medical degree from the University of London and an MBA from New York University Stern School of Business.
Financial terms:
Latest news:
